Showing: 1 - 1 of 1 RESULTS

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

For Immediate Release

Chicago, IL – October 13, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Emergent BioSolutions Inc. EBS, Vertex Pharmaceuticals Incorporated VRTX, Editas Medicine, Inc. EDIT, Cellectis S.A. CLLS and Thermo Fisher Scientific Inc. TMO.

Here are highlights from Monday’s Analyst Blog:

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

The biotech space has been booming in the past decade, with areas like gene editing stealing the show as they increase scope for treating life-threatening diseases. Gene editing or genome engineering is a process in which a DNA is inserted, modified or replaced in the genome of any living organism. In recent years, scientists have been using gene editing technology to help treat diseases with a genomic basis, like cystic fibrosis, diabetes and cancer.

CRISPR or “Clustered Regularly Interspaced Short Palindromic Repeats” is a tool primarily used to edit genes at present. Many scientists believe that this year could be a breakthrough in finding cures for cancer in DNA and investors could get familiar with terms like CRISPR and precision medicine to make the most out of advancements in this space.

Additionally, the coronavirus outbreak has pushed scientists to look for a cure through gene editing, as this novel virus keeps wreaking havoc and claiming millions of lives globally.

Disruptive Biotech Making a Mark in 2020

Cancer has been the second-leading cause of death in the United States over the past few years. Per Centers for Disease Control and Prevention (CDC) data, nearly 599,108 people lost their lives due to cancer in 2019. Gene editing has now opened up ways in which alterations in the DNA will allow patients to train their body to destroy life-threatening tumors.

Additionally, utilization of order writing techniques to rewrite infected cells and tissues, and removal of harmful mutations are also expected to boost this space. Several biotech firms are now using immuno-oncology treatments in which the immuno-oncology class of drugs teach or direct the immune system to identify cancer and then destroy it. In fact, techniques like correction within the harmful mutations, disruption of infectious agent in the DNA, or the addition of therapeutic transgenes are boosting the gene editing market.

According to Emergen Research report, the global gene editing market is projected to reach $15.79 billion by 2027 from $4.44 billion in 2019, at a CAGR of 17.2%.

One of the recent gene editing tools worth mentioning is the PAC-MAN or Prophylactic Antiviral CRISPR in human cells tool. Stanford University scientists have developed an antiviral agent against the novel coronavirus that can target and destroy specific genetic strands of the virus inside the human cell itself. The PAC-MAN which is composed of an enzyme and a strand of guide RNA has provided promising results in the laboratory when tested on human lung cells infected with SARS-CoV-2.        

2020